MARKET

AVRO

AVRO

AVROBIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.25
+0.04
+0.28%
After Hours: 14.25 0 0.00% 16:00 10/22 EDT
OPEN
14.39
PREV CLOSE
14.21
HIGH
14.62
LOW
14.11
VOLUME
82.80K
TURNOVER
--
52 WEEK HIGH
33.39
52 WEEK LOW
11.85
MARKET CAP
317.97M
P/E (TTM)
-5.6096
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AVRO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AVRO News

  • AVROBIO Appoints Holly May as Chief Commercial Officer
  • Business Wire.15h ago
  • Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
  • Simply Wall St..6d ago
  • AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
  • Business Wire.10/08 12:00
  • Avrobio launches mid-stage study of AVR-RD-04 for cystinosis
  • Seeking Alpha - Article.10/08 11:41

More

Industry

Biotechnology & Medical Research
+0.44%
Pharmaceuticals & Medical Research
+0.60%

Hot Stocks

Name
Price
%Change

About AVRO

AVROBIO, Inc. is a clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.
More

Webull offers Avrobio Inc (AVRO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.